Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015)

Market Cap	8.99B -20.0%
Revenue (ttm)	1.46B +14.8%
Net Income	447.34M +28.0%
EPS	6.39 +28.0%
Shares Out	70.00M
PE Ratio	20.09
Forward PE	17.47
Dividend	3.06 (2.37%)
Ex-Dividend Date	Mar 2, 2026

Volume	49,402
Average Volume	99,643
Open	129.90
Previous Close	129.30
Day's Range	126.60 - 129.90
52-Week Range	125.00 - 183.80
Beta	0.57
RSI	41.14
Earnings Date	Feb 24, 2026

About TADAWUL:4015

Jamjoom Pharmaceuticals Factory Company, together with its subsidiaries, engages in the manufacture and distribution of pharmaceutical and consumer products in the Kingdom of Saudi Arabia, Gulf, Iraq, Egypt, North Africa, and internationally. The company offers human medicines; nutraceuticals; antibiotics; general analgesics; medicines for treatment of cough, allergy, asthma, heart diseases, blood pressure, diarrhea, vomiting, and ulcer and acidity; treatment of various skin infections and cancer diseases; and eye drops, and ointments and cosme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 1,255
• Stock Exchange: Saudi Stock Exchange
• Ticker Symbol: 4015

Financial Performance

In 2024, TADAWUL:4015's revenue was 1.32 billion, an increase of 19.77% compared to the previous year's 1.10 billion. Earnings were 356.52 million, an increase of 21.93%.